Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2018 | 12 | 3 |
Tytuł artykułu

Importance of cannabinoids in the functioning of the central nervous system

Warianty tytułu
Znaczenie kannabinoidów w funkcjonowaniu ośrodkowego układu nerwowego
Języki publikacji
At present, there is a great emphasis of public opinion on the legalisation of medical marijuana, i.e. the top parts of the cannabis plants rich in tetrahydrocannabinol (THC). Nevertheless, in the cannabis plants, there are many various cannabinoids, including cannabidiol (CBD). Scientific reports to-date indicate the possibility for using pharmacologically active cannabinoids in the treatment of such diseases/symptoms as: anorexia, vomiting, neuropathic pain, inflammatory diseases, multiple sclerosis, degenerative diseases of the central nervous system (Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, Tourette’s syndrome), epilepsy, schizophrenia, and obesity. The article presents up-to-date information on the results of experimental studies concerning the effectiveness of cannabinoids, with particular consideration of diseases related with the central nervous system, including epilepsy, neuropathic pain, mental disorders, as well as obesity and anorexia.
Aktualnie obserwuje się duży nacisk opinii społecznej na legalizację medycznej marihuany, czyli szczytowych części roślin konopi indyjskich bogatych w tetrahydrokannabinol (THC). Tymczasem, w konopiach jest wiele różnych kannabinoidów, między innymi kannabidiol (CBD). Aktualne doniesienia naukowe wskazują na możliwość wykorzystania farmakologicznej aktywności kannabinoidów w obszarze leczenia takich chorób/ objawów jak: anoreksja, wymioty, ból neurogenny, choroby zapalne, stwardnienie rozsiane, choroby degeneracyjne ośrodkowego układu nerwowego (choroba Parkinsona, Huntingtona, Alzheimera oraz zespół Tourette’a), padaczka, schizofrenia, otyłość. W pracy przedstawiono aktualne informacje na temat wyników prowadzonych dotychczas badań nad skutecznością kannabinoidów, ze szczególnym uwzględnieniem chorób związanych z ośrodkowym układem nerwowym, w tym: padaczką, bólem neuropatycznym, chorobami psychicznymi oraz otyłością i anoreksją.
Opis fizyczny
  • Department of Pathophysiology, Medical University in Lublin, Lublin, Poland
  • Department of Medical Anthropology, Institute of Rural Health in Lublin, Lublin, Poland
  • Department of Pathophysiology, Medical University in Lublin, Jaczewskiego 8, 20-090 Lublin, Poland
  • 1. Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep. 2009; 61:217–24.
  • 2. Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R. Perceived efficacy of cannabidiol-enriches cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut sundrome. Epilepsy Behav. 2015; 47:138–41.
  • 3. Harvey DJ. Absorption, Distribution, and Biotransformation of the Cannabinoids. In: Nahas GG, Sutin KM, Harvey D, Agurell S, Pace N, Cancro R., editors. Marihuana and Medicine. Humana Press, Totowa, NJ; 1999.
  • 4. Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012; 18: 4966–79.
  • 5. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics. 2015; 12(4): 807-15.
  • 6. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012; 2: e94.
  • 7. Glass M, Felder C. Concurrent simulation of cannabinoid CB1 and dopamine D2 receptor augments Camp accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci. 1997; 17(4): 5327-33.
  • 8. Devane W, Hanus L, Breuer A, Pertwee R, Stevenson L, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Scien. 1992; 258: 1946-9.
  • 9. Pertwee R. Evidence for the presence of CB1 cannabinoid receptor on peripheral neurons and for the existence of neuronal non-CB1 cannabinoid receptor. Life Sci. 1999; 65: 597-605.
  • 10. Perrot S. Cannabis: the analgesic and anti−inflammatory medication of the future? Joint Bone Spine. 2004; 71: 7–8.
  • 11. Rutkowska M, Jamontt J. The role of cannabinoid system in the physiology and the pathophysiology of the central nervous system. Adv Clin Exp Med. 2005; 14(6): 1243–52.
  • 12. Brooks JW. Cannabinoids and analgesia. Curr Anaesth Crit Care. 2002; 13: 215–20.
  • 13. Griffin G, Fernando S, Ross R, McKay N, Ashford M, Shire D, et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol. 1997; 339:53-61.
  • 14. Munro S, Thomas K, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: 61-5.
  • 15. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology. 2006; 54(4): 231-46.
  • 16. Childers SR, Breivogel CS. Cannabis and endogennous cannabinoid systems. Drug Alcohol Depend. 1998; 51: 173–87.
  • 17. Breivogel CS, Griffin G, Di Marzo V, Martin B R. Evidence for a new G protein−coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001; 60: 155–63.
  • 18. Iversen L, Chapman V. Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol. 2002; 2: 50–5.
  • 19. Volfe Z, Dvilansky A, Nathan I. Cannabinoids block release of serotonin from plates induced by plasma from migraine patients. Int J Clin Pharmacol Res. 1985; 8: 243-6.
  • 20. Russo E, Guy G. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and canabidiol. Med Hypotheses. 2006; 66: 234-46.
  • 21. Rog D, Nurmikko T, Friede T, Young C. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005; 65(6): 812-9.
  • 22. Beal J, Olson R, Lefkowitz L. Long-term efficacy and safety of dronabinol for acquired immunodefi ciency syndrome-associated anorexia. J Pain Symptom Manage. 1997; 14: 7-14.
  • 23. Randall MD, Kendall DA, Bennett AJ, O’Sullivan SE. Rimonabant in obese patients with type 2 diabetes. Lancet. 2007; 369(9561): 555.
  • 24. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001; 410: 822–5.
  • 25. Mechoulam R, Carlini E A. Toward drugs derived from cannabis. Naturwissenschaften. 1978; 65: 174–9.
  • 26. Cota D, Marscicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003; 112: 423–31.
  • 27. Van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol. 2003; 480: 133–50.
  • 28. Bruinsma K, Taren DL. Chocolate: food or drug? J Am Diet Assoc. 1999; 99: 1249–56.
  • 29. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry. 2001; 178: 107–15.
  • 30. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, et al. Effects of dronabinol on nutritional status in HIV infection. An Pharmacother. 1993; 27: 827–31.
  • 31. Ravinet Trillou C, Arnone M, Delgore C, Gonalons N, Keane P, Maffrand JP, et al. Anti−obesity effect of SR 141716, a CB1 receptor antagonist, in diet – induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003; 284: 345–53.
  • 32. Fernandez JR, Allison DB. Rimonabant Sanofi−Synthelabo. Curr Opin Investig Drugs. 2004; 5: 430–5.
  • 33. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology. 2002; 159: 379–87.
  • 34. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003; 70: 83–244.
  • 35. De Miguel R, Hernandez−Tristan R. Cannabinoid effects on anxiety – related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav. 2001; 70: 123–31.
  • 36. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000; 60: 1303–14.
  • 37. Campos AC, Fogaca MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 2016; 112: 119–27.
  • 38. Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016; 96: 1593–659.
  • 39. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004; 29: 417–26.
  • 40. Pedrazzi JF, Issy AC, Gomes FV, Guimarães FS, Del-Bel EA. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl). 2015; 232:3057–65.
  • 41. Renard J, Loureiro M, Rosen LG, Zunder J, de Oliveira C, Schmid S, et al. Cannabidiol counteracts amphetamineinduced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR/p70S6 Kinase Signaling Pathway. J. Neurosci. 2016; 36: 5160–9.
  • 42. Guimarães VM, Zuardi AW, Del Bel EA, Guimarães FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 2004; 75: 633–8.
  • 43. Campos AC, Moreira FA, Gomes FV. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607): 3364-78.
  • 44. Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2011; 38: 2433-6.
  • 45. Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des. 2012; 18(32): 5131-40.
  • 46. Schier de Mello AR, de Oliveira Ribeiro PN, Coutinho S, Machado S, Arias-Carrión O, Crippa JA, et al. Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014; 13(6): 953-60.
  • 47. Abboud R, Sanders H. Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and athmatic subjects. Chest. 1976; 70: 480-5.
  • 48. Filipović D, Todorović N, Bernardi RE, Gass P. Oxidative and nitrosative stress pathways in the brain of socially isolated adult male rats demonstrating depressive- and anxiety-like symptoms. Brain Struct. Funct. 2017; 222: 1–20.
  • 49. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999; 58: 315–48.
  • 50. Glass M. The role of the cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiat. 2001; 25: 743–65.
  • 51. Lastres-Becker I, Molina-Holgado F, Ramos J, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis. 2005; 19: 96-107.
  • 52. Lastres-Becker L, De Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernandez-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid system reduce hyperkinesia in a rat model of Huntington’s disease. J Neurochem. 2003; 84: 1097-109.
  • 53. Muller-Vahl K, Prevedel H, Th eloe K, Kolbe H, Emrich H, Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology. 2003; 28: 384-8.
  • 54. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been… . Headache. 2015; 55(6): 885– 916.
  • 55. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015; 373(11): 1048– 58.
  • 56. Campbell CT, Phillips MS, Manasco K. Cannabinoids in Pediatrics. J Pediatr Pharmacol Ther. 2017; 22(3): 176-85.
  • 57. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy-from receptors to clinical response. Epilepsy Behav. 2014; 41:277-82.
  • 58. Santos RG, Hallak JEC, Leite JP, Zuardi AW, Crippa JA. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2014; 40(2): 135-43.
  • 59. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015; 17: 117–23.
  • 60. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014; 55:783–6.
  • 61. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1985; 69(1): 14.
  • 62. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175–85.
  • 63. Mechoulam R, Fride E. A hunger for cannabinoids. Nature. 2001; 410: 763–5. 10.1038/35071214
  • 64. Welty TE, Luebke A, Gidal BE. Cannabidiol: promise and pitfalls. Epilepsy Curr. 2014; 14(5): 250-2.
  • 65. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014; 55:791–802.
  • 66. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015; 56: 1246–51.
  • 67. Consroe P, Martin A, Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol. 1981; 21:428S-36S.
  • 68. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis for treatment of refractory epilepsy. Epilepsy Behav. 2015; 45:49–52.
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.